Hyperthermia and radiotherapy in bladder cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015;65:5–29.
   PubMed Web of Science ®Google Scholar
• Gattegno B. T1G3 bladder cancer: conservative management or cystectomy? Eur Urol 2004;45:399–400.
   PubMed Web of Science ®Google Scholar
• Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years. Eur Urol 2004;45:730–5.
   PubMed Web of Science ®Google Scholar
• Malavaud B. T1G3 bladder tumours: the case for radical cystectomy. Eur Urol 2004;45:406–10.
   PubMed Web of Science ®Google Scholar
• Thalmann GN, Markwalder R, Shahin O, Burkhard FC, Hochreiter WW, Studer UE. Primary T1G3 bladder cancer: organ preserving approach or immediate cystectomy? J Urol 2004;172:70–5.
   PubMed Web of Science ®Google Scholar
• Turner W. T1G3 bladder tumours: the case for conservative treatment. Eur Urol 2004;45:401–5.
   PubMed Web of Science ®Google Scholar
• Patard JJ, Rodriguez A, Leray E, Rioux-Leclercq N, Guillé F, Lobel B. Intravesical Bacillus Calmette-Guerin treatment improves patient survival in T1G3 bladder tumours. Eur Urol 2002;41:635–41.
   PubMed Web of Science ®Google Scholar
• Manoharan M, Soloway MS. Optimal management of the T1G3 bladder cancer. Urol Clin North Am 2005;32:133–45.
   PubMed Web of Science ®Google Scholar
• Shahin O, Thalmann GN, Rentsch C, Mazzucchelli L, Studer UE. A retrospective analysis of 153 patients treated with or without intravesical bacillus Calmette-Guerin for primary stage T1 grade 3 bladder cancer: recurrence, progression and survival. J Urol 2003;169:96–100.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466–5.
   PubMed Web of Science ®Google Scholar
• Clark PE, Agarwal N, Biagioli MC, Eisenberger MA, Greenberg RE, Herr HW, et al. Bladder cancer. J Natl Compr Canc Netw 2013;11:446–75.
   PubMed Web of Science ®Google Scholar
• Ark JT, Keegan KA, Barocas DA, Morgan TM, Resnick MJ, You C, et al. Incidence and predictors of understaging in patients with clinical T1 urothelial carcinoma undergoing radical cystectomy. BJU Int 2014;113:894–9.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009;55:815–25.
   PubMed Web of Science ®Google Scholar
• Madersbacher S, Hochreiter W, Burkhard F, Thalmann GN, Danuser H, Markwalder R, et al. Radical cystectomy for bladder cancer today – a homogeneous series without neoadjuvant therapy. J Clin Oncol 2003;21:690–6.
   PubMed Web of Science ®Google Scholar
• Hautmann RE, Gschwend JE, de Petriconi RC, Kron M, Volkmer BG. Cystectomy for transitional cell carcinoma of the bladder: results of a surgery only series in the neobladder era. J Urol 2006;176:486–92.
   PubMed Web of Science ®Google Scholar
• Rosenkrantz AB, Mussi TC, Melamed J, Taneja SS, Huang WC. Bladder cancer: utility of MRI in detection of occult muscle-invasive disease. Acta Radiol 2012;53:695–9.
   PubMed Web of Science ®Google Scholar
• Kassouf W, Hautmann RE, Bochner BH, Lerner SP, Colombo R, Zlotta A, et al. A critical analysis of orthotopic bladder substitutes in adult patients with bladder cancer: is there a perfect solution? Eur Urol 2010;58:374–83.
   PubMed Web of Science ®Google Scholar
• Böhle A, Bock PR. Intravesical bacille Calmette-Guérin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progression. Urology 2004;63:682–6.
   Web of Science ®Google Scholar
• Malmström PU, Sylvester RJ, Crawford DE, Friedrich M, Krege S, Rintala E, et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol 2009;56:247–56.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 2005;174:86–91.
   PubMed Web of Science ®Google Scholar
• Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002;168:1964–70.
   PubMed Web of Science ®Google Scholar
• Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000;163:1124–9.
   PubMed Web of Science ®Google Scholar
• Coppin CM, Gospodarowicz MK, James K, Tannock IF, Zee B, Carson J, et al. Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1996;14:2901–7.
   PubMed Web of Science ®Google Scholar
• James ND, Hussain SA, Hall E, Jenkins P, Tremlett J, Rawlings C, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med 2012;366:1477–88.
   PubMed Web of Science ®Google Scholar
• International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group); European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group; Finnbladder, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171–7.
   PubMed Web of Science ®Google Scholar
• Pollack A, Zagars GK, Swanson DA. Muscle-invasive bladder cancer treated with external beam radiotherapy: prognostic factors. Int J Radiat Oncol Biol Phys 1994;30:267–77.
   PubMed Web of Science ®Google Scholar
• Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 2001;19:666–75.
   PubMed Web of Science ®Google Scholar
• Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol 2007;4:172–80.
   PubMedGoogle Scholar
• Tunio MA, Hashmi A, Qayyum A, Mohsin R, Zaeem A. Whole-pelvis or bladder-only chemoradiation for lymph node-negative invasive bladder cancer: single-institution experience. Int J Radiat Oncol Biol Phys 2012;82:e457–62.
   PubMed Web of Science ®Google Scholar
• Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:3576–83.
   PubMed Web of Science ®Google Scholar
• Housset M, Maulard C, Chretien Y, Dufour B, Delanian S, Huart J, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol 1993;11:2150–7.
   PubMed Web of Science ®Google Scholar
• Efstathiou JA, Spiegel DY, Shipley WU, Heney NM, Kaufman DS, Niemierko A, et al. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705–11.
   PubMed Web of Science ®Google Scholar
• Mitin T, Hunt D, Shipley WU, Kaufman DS, Uzzo R, Wu CL, et al. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncol 2013;14:863–72.
   PubMed Web of Science ®Google Scholar
• Kotwal S, Choudhury A, Johnston C, Paul AB, Whelan P, Kiltie AE. Similar treatment outcomes for radical cystectomy and radical radiotherapy in invasive bladder cancer treated at a United Kingdom specialist treatment center. Int J Radiat Oncol Biol Phys 2008;70:456–63.
   PubMed Web of Science ®Google Scholar
• Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol 2012;61:1039–47.
   PubMed Web of Science ®Google Scholar
• Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J Urol 2014;191:40–7.
   PubMed Web of Science ®Google Scholar
• Kachnic LA, Kaufman DS, Heney NM, Althausen AF, Griffin PP, Zietman AL, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol 1997;15:1022–9.
   PubMed Web of Science ®Google Scholar
• Kaufman DS, Winter KA, Shipley WU, Heney NM, Chetner MP, Souhami L, et al. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist 2000;5:471–6.
   PubMedGoogle Scholar
• Weiss C, Engehausen DG, Krause FS, Papadopoulos T, Dunst J, Sauer R, et al. Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer. Int J Radiat Oncol Biol Phys 2007;68:1072–80.
   PubMed Web of Science ®Google Scholar
• Lagrange JL, Bascoul-Mollevi C, Geoffrois L, Beckendorf V, Ferrero JM, Joly F, et al. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys 2011;79:172–8.
   PubMed Web of Science ®Google Scholar
• Gogna NK, Matthews JH, Turner SL, Mameghan H, Duchesne GM, Spry N, et al. Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: a report of two sequential phase II studies from the Trans Tasman Radiation Oncology Group. Radiother Oncol 2006;81:9–17.
   PubMed Web of Science ®Google Scholar
• Zapatero A, Martin De Vidales C, Arellano R, Ibañez Y, Bocardo G, Perez M, et al. Long-term results of two prospective bladder-sparing trimodality approaches for invasive bladder cancer: neoadjuvant chemotherapy and concurrent radio-chemotherapy. Urology 2012;80:1056–62.
   PubMed Web of Science ®Google Scholar
• Dewhirst MW, Sim D, Gross J. Effects of heating rate on normal and tumor microcirculatory function. In: Diller K, Roemer RB, eds. Heat and mass transfer in the microcirculation of thermally significant vessels. Anaheim, CA: ASME 1986:75–80.
   Google Scholar
• Streffer C. Metabolic changes during and after hyperthermia. Int J Hyperthermia 1985;1:305–19.
   PubMedGoogle Scholar
• Oleson JR. Eugene Robertson Special Lecture. Hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia 1995;11:315–22.
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Poulson JM, Gaskin AA, Thrall DE, Page RL, Charles HC, et al. Temperature-dependent changes in physiologic parameters of spontaneous canine soft tissue sarcomas after combined radiotherapy and hyperthermia treatment. Int J Radiat Oncol Biol Phys 2000;46:179–85.
   PubMed Web of Science ®Google Scholar
• Zywietz F, Reeker W, Kochs E. Changes in tumor oxygenation during a combined treatment with fractionated irradiation and hyperthermia: An experimental study. Int J Radiat Oncol Biol Phys 1997;37:155–62.
   PubMed Web of Science ®Google Scholar
• Brizel DM, Scully SP, Harrelson JM, Layfield LJ, Dodge RK, Charles HC, et al. Radiation therapy and hyperthermia improve the oxygenation of human soft tissue sarcomas. Cancer Res 1996;56:5347–50.
   PubMed Web of Science ®Google Scholar
• Thrall DE, Larue SM, Pruitt AF, Case B, Dewhirst MW. Changes in tumour oxygenation during fractionated hyperthermia and radiation therapy in spontaneous canine sarcomas. Int J Hyperthermia 2006;22:365–73.
   PubMed Web of Science ®Google Scholar
• Jones EL, Prosnitz LR, Dewhirst MW, Marcom PK, Hardenbergh PH, Marks LB, et al. Thermochemoradiotherapy improves oxygenation in locally advanced breast cancer. Clin Cancer Res 2004;10:4287–93.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Kallinowski F, Kluge M. Pathophysiology of tumors in hyperthermia. Recent Results Cancer Res 1988;107:65–75.
   PubMedGoogle Scholar
• Dewey WC, Hopwood LE, Sapareto SA, Gerweck LE. Cellular responses to combinations of hyperthermia and radiation. Radiology 1977;123:463–74.
   PubMed Web of Science ®Google Scholar
• Oei AL, Vriend LE, Crezee J, Franken NA, Krawczyk PM. Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all. Radiat Oncol 2015;10:165.
   PubMed Web of Science ®Google Scholar
• Datta NR, Ordóñez SG, Gaipl US, Paulides MM, Crezee H, Gellermann J, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: Recent advances and promises for the future. Cancer Treat Rev 2015;41:742–53.
   PubMed Web of Science ®Google Scholar
• Matsui K, Takebayashi S, Watai K, Kakehi M, Kubota Y, Yao M, et al. Combination radiotherapy of urinary bladder carcinoma with chemohyperthermia. Int J Hyperthermia 1991;7:19–26.
   PubMed Web of Science ®Google Scholar
• Kubota Y, Shuin T, Miura T, Nishimura R, Fukushima S, Takai S. Treatment of bladder cancer with a combination of hyperthermia, radiation and bleomycin. Cancer 1984;53:199–202.
   PubMed Web of Science ®Google Scholar
• Takechi T, Kawamura M, Nakagawa H, Inatsuki S, Akiyama K, Yano M, et al. Combined treatment in patients with carcinoma in situ of the urinary bladder using intravesical pirarubicin, irradiation and hyperthermia. Nihon Gan Chiryo Gakkai Shi 1990;25:2724–7.
   PubMedGoogle Scholar
• Masunaga SI, Hiraoka M, Akuta K, Nishimura Y, Nagata Y, Jo S, et al. Phase I/II trial of preoperative thermoradiotherapy in the treatment of urinary bladder cancer. Int J Hyperthermia 1994;10:31–40.
   PubMed Web of Science ®Google Scholar
• Noguchi S, Kubota Y, Miura T, Shuin T, Hosaka M. Use of methotrexate, vinblastine, Adriamycin, and cisplatin in combination with radiation and hyperthermia as neo-adjuvant therapy for bladder cancer. Cancer Chemother Pharmacol 1992;30:S63–5.
   PubMed Web of Science ®Google Scholar
• Ohguri T, Imada H, Nomoto S, Kato F, Yahara K, Morioka T, et al. Initial experience of bladder preservation therapy using chemoradiotherapy with regional hyperthermia for muscle-invasive bladder cancer. Jpn J Hyperthermic Oncol 2005:21:151–8.
   Google Scholar
• Wittlinger M, Rödel CM, Weiss C, Krause SF, Kühn R, Fietkau R, et al. Quadrimodal treatment of high-risk T1 and T2 bladder cancer: transurethral tumor resection followed by concurrent radiochemotherapy and regional deep hyperthermia. Radiother Oncol 2009;93:358–63.
   PubMed Web of Science ®Google Scholar
• McDougal WS, Shipley WU, Kaufman DS, Dahl DM, Michaelson MD, Zietman AL. Cancer of the bladder, ureter, and renal pelvis. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology, 9th ed. Philadelphia: Lippincott Williams & Wilkins; 2011, pp. 1192–211.
   Google Scholar
• Colombo R, Da Pozzo LF, Lev A, Freschi M, Gallus G, Rigatti P. Neoadjuvant combined microwave induced local hyperthermia and topical chemotherapy versus chemotherapy alone for superficial bladder cancer. J Urol 1996;155:1227–32.
   PubMed Web of Science ®Google Scholar
• Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, et al. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer. Urology 2004;63:466–71.
   PubMed Web of Science ®Google Scholar
• Colombo R, Salonia A, Da Pozzo LF, Naspro R, Freschi M, Paroni R, et al. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience. Crit Rev Oncol Hematol 2003;47:127–39.
   PubMed Web of Science ®Google Scholar
• Moskovitz B, Meyer G, Kravtzov A, Gross M, Kastin A, Biton K, et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005;16:585–9.
   PubMed Web of Science ®Google Scholar
• Colombo R, Da Pozzo LF, Salonia A, Rigatti P, Leib Z, Baniel J, et al. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma. J Clin Oncol 2003;21:4270–6.
   PubMed Web of Science ®Google Scholar
• Van der Heijden AG, Kiemeney LA, Gofrit ON, Nativ O, Sidi A, Leib Z, et al. Preliminary European results of local microwave hyperthermia and chemotherapy treatment in intermediate or high risk superficial transitional cell carcinoma of the bladder. Eur Urol 2004;46:65–71.
   PubMed Web of Science ®Google Scholar
• Van der Zee J, González González D, van Rhoon GC, van Dijk JD, van Putten WL, Hart AA. Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 2000;355(9210):1119–25.
   PubMed Web of Science ®Google Scholar
• Hata M, Miyanaga N, Tokuuye K, Saida Y, Ohara K, Sugahara S, et al. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy. Int J Radiat Oncol Biol Phys 2006;64:1371–9.
   PubMed Web of Science ®Google Scholar
• Datta NR, Puric E, Schneider R, Weber DC, Rogers S, Bodis S. Could hyperthermia with proton therapy mimic carbon ion therapy? Exploring a thermo-radiobiological rationale. Int J Hyperthermia 2014;30:524–30.
   PubMed Web of Science ®Google Scholar